Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...
M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al.· bioRxiv· 0 citations
An ensemble approach (enFoldX) that leverages structure prediction models such as AlphaFold3 to build sensitive binding predictors and outperforms the current co-folding methods which rely on predictions from the single top ranked structure.
O. Lyudovyk, Jonathan A. Levine, M. Pathil et al.· Clinical Cancer Research· 0 citations
An ensemble approach (enFoldX) that leverages structure prediction models such as AlphaFold3 to build sensitive binding predictors and outperforms the current co-folding methods which rely on predictions from the single top ranked structure.
O. Lyudovyk, Jonathan A. Levine, M. Pathil et al.· Clinical Cancer Research· 0 citations
Adaptive immunity relies on T-cell receptor (TCR) recognition of peptides presented by the major histocompatibility complex (pMHC). Accurate prediction of TCR:pMHC binding pairs from sequence data remains a longstanding challenge in computational immunology, limiting the development of precision immunotherapies like ca...
O. Lyudovyk, JA Levine, M. Pathil et al.· bioRxiv· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
